The tariff conversation is already happening in your hospital procurement meetings.
Most medtech commercial leaders have not been in this situation before, because for the better part of two decades, the industry operated effectively tariff-free. That has now changed, and the skill set required to lead a commercial team in this environment is not the same as the one that worked through the previous decade.
The Section 232 investigation into medical device imports has been running since September 2025. It covers everything from syringes and IV pumps to pacemakers and imaging machines. The Supreme Court struck down the IEEPA tariff mechanism in February, which means Section 232 has now emerged as the primary instrument for securing critical healthcare supply chains. A decision is expected by summer. The pharmaceutical Executive Order two weeks ago confirms the administration is not losing momentum.
For medtech commercial leaders, the uncertainty itself is already the operating environment, regardless of the final outcome.
Hospital procurement teams have been asking about price stability since Q4 last year. Value analysis committees that previously focused on clinical evidence and per-procedure cost are now asking about import exposure and whether pricing guarantees are viable. Industry analysis indicates that even 50 basis-point movements in supply costs represent significant margin events for major hospital systems. That number matters because it tells you exactly what the procurement director across the table is already calculating.
To be clear about the scale of the problem: analysts characterise the overall tariff headwind as manageable so far, with most companies still growing earnings despite the impact. But "manageable at the large company level" conceals a different reality for smaller medtech businesses. AngioDynamics reported tariff-related expenses of $1.3 million in a single quarter, with a full-year 2026 impact projected at $4 to $6 million, contributing to a 110 basis-point year-on-year compression in gross margin. For a company of that size, 110 basis points is not a rounding error. It is the conversation your commercial leader is walking into every time they sit down with a hospital procurement director.
The commercial leader who can hold that pricing conversation with confidence, who understands the downstream implications of import cost movements for hospital margins, and who neither capitulates nor collapses under pressure is a genuinely different hire from the one who has spent their career in stable pricing conditions, selling on clinical outcomes alone.
The question I have been asking every client brief right now is this: has this candidate operated in a pricing environment where the cost structure was moving beneath them, and did they grow revenue through it, or did they wait for stability that never arrived? The answer tells you more about likely performance over the next eighteen months than their existing network or their CV does.
Most commercial leaders who built their formative experience in the 2010s have not managed through this kind of structural cost pressure. That is not a criticism. It is a generational gap in experience. The ones who have, often those who came up through companies operating in highly tender-driven European markets, in NHS capital equipment cycles, or in markets where distributor pricing was constantly under renegotiation, carry a capability that is suddenly extremely relevant.
Section 232 will resolve eventually. Pricing pressure will not.